TBPMF News and Press, Tetra Bio-Pharma Inc From 02/05/19

ORLEANS, Ontario, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administ...

Crescita Therapeutics ( OTC:CRRTF ) and Tetra Natural Health, a subsidiary of Tetra Bio-Pharma ( OTCQB:TBPMF ) collaborates to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ...

LAVAL, Quebec, and ORLEANS, Ontario, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Crescita Therapeutics Inc. ("Crescita") (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and developme...

Tetra Bio-Pharma ( OTCQB:TBPMF ) has agreed to acquire cannabinoid-based drug developer Panag Pharma  for $12M in cash and stock. More news on: Tetra Bio-Pharma Inc., Healthcare stocks news, Merger & acquisition news, Read more ...

Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc. Canada NewsWire ORLEANS, ON, Jan. 30, 2019 The Proposed Transaction is expected to: provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabino...

ORLEANS, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc  (“ Tetra ” or the “ Company ”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent applicati...